drugset / Trial / NCT01194856
Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression
Phase 4
Terminated
1 enrolled
The Cleveland Clinic
Bristol-Myers Squibb · collabCase Western Reserve University · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedCrossoverOpen-labelTreatment
Summary
The purposes of this study are to evaluate if switching an antiretroviral medication from efavirenz (EFV) to atazanavir/ ritonavir (ARV/r) will, in a 96-week period, change: 1. the amount of fat in HIV patients with lipoatrophy, 2. metabolic lab values such as your lipid (fat) profile, glucose (blood sugar), and insulin (a hormone that regulates glucose) in HIV patients with lipoatrophy.
Timeline
- Start
- 2010-10
- Primary completion
- 2011-12
- Completion
- 2011-12
Outcome
Outcome not reported
Stopped (Enrollment): “Closed due to low enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atazanavir | Other / unclassified | 300 mg | Oral |
| Comparator | Efavirenz | Other / unclassified | 600 mg | Oral |
| Subject | Ritonavir | Other / unclassified | 100 mg | Oral |